Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 11, 2023Journal of Thoracic OncologyOpen Access

Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301

View Full Paper
Ask AI
Bookmark
Share

Authors

TRThanyanan ReungwetwattanaMahidol UniversityBCByoung Chul ChoUlsan CollegeKLKi Hyeong LeeChungbuk National University Hospital

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Reungwetwattana et al. (2023) studied this question.

synapsesocial.com/papers/6aa63febd3d41ccc68922ee5https://doi.org/10.1016/j.jtho.2023.06.016
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors2021 · 94 citations
  2. 2AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations2022 · 302 citations
  3. 3Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer2019 · 380 citations